## MTD: Mettler-Toledo International, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.6% below STRENGTH zone (3.0-6.0%); PEG 3.64 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1298.12)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Walleye Trading LLC Purchases 998 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251208T132031 | Somewhat-Bullish | Relevance: 100%
-  Walleye Trading LLC significantly increased its stake in Mettler-Toledo International, Inc. (NYSE: MTD) by 499% in Q2, acquiring an additional 998 shares and bringing its total holdings to 1,198 shares valued at approximately $1.41 million. This increase comes as Mettler-Toledo reported strong Q3 earnings, beating analyst expectations for both EPS and revenue, and issued robust FY2025 guidance. Despite positive institutional investor activity, there has been notable insider selling by the CEO and another insider, totaling around $28.68 million in the last 90 days.

**2. Amundi Sells 9,062 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251208T170848 | Neutral | Relevance: 98%
-  Amundi has reduced its stake in Mettler-Toledo International, Inc. by 7.5%, selling 9,062 shares and now holding 111,247 shares valued at approximately $134.13 million. Recent insider transactions show significant selling by company executives, totaling $28.68 million in the past three months. Analysts currently have a "Hold" consensus rating on the stock with a price target of $1,419.55, though some have recently raised their targets.

**3. The Goldman Sachs Group Begins Coverage on Mettler-Toledo International (NYSE:MTD)**
- Source: MarketBeat | 20251209T133331 | Neutral | Relevance: 98%
-  The Goldman Sachs Group initiated coverage on Mettler-Toledo International (NYSE:MTD) with a "neutral" rating and a $1,475.00 price target, suggesting a potential upside of 6.69% from its current trading price. This new coverage joins other recent analyst reports, resulting in a consensus "Hold" rating and an average target price of $1,424.17 for the medical instruments supplier. Mettler-Toledo International recently reported strong quarterly earnings, beating analyst expectations, and several institutional investors have adjusted their stakes in the company.

**4. Goldman Sachs Initiates Coverage on Mettler-Toledo (MTD) with Ne**
- Source: GuruFocus | 20251209T140824 | Somewhat-Bullish | Relevance: 98%
-  Goldman Sachs has initiated coverage on Mettler-Toledo International Inc. (MTD) with a 'Neutral' rating and a price target of $1,475.00 USD. This report highlights recent analyst activities and forecasts for MTD, noting an average target price of $1,490.41 from 13 analysts, suggesting an upside of 7.89% from its current price. Mettler-Toledo specializes in weighing and precision instruments for life sciences, industrial, and food retail sectors.

**5. Mettler-Toledo Stock: Is MTD Underperforming the Healthcare Sector?**
- Source: inkl | 20251208T120819 | Somewhat-Bullish | Relevance: 98%
-  Mettler-Toledo International Inc. (MTD) is a leader in precision instruments with a market cap of $28.9 billion. While MTD shares have underperformed the Health Care Select Sector SPDR Fund (XLV) in the last three months, they have outpaced XLV year-to-date and over the past 52 weeks. Despite recent fluctuations and a slight dip after better-than-expected Q3 earnings, analysts maintain a "Moderate Buy" rating for MTD, suggesting a 7% upside.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $1475 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $1550 | $0 | 0% |
| 2025-11-10 | Citigroup | $1700 | $1600 | +6% |
| 2025-11-10 | Barclays | $1600 | $1350 | +19% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Neutral |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |
| 2025-11-10 | Citigroup | main | Buy |
| 2025-11-10 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 18 ($1.28M) |
| Sells | 6 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+1.4%)
- Blackrock Inc.: 9.2% (-3.1%)
- State Street Corpora: 4.7% (-0.5%)
- Capital Internationa: 4.2% (+1.2%)
- Bank Of New York Mel: 4.0% (-9.0%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.1% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.6x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.64 signals overvaluation risk, limited margin of safety. Forward P/E 30.0x stretched relative to 8% growth. Quality metrics strong (ROE 30%, ROA 20%, margin 21%). Analyst sentiment positive (4 raises, avg +13%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $28.2B |
| Beta | 1.40 |
| 52W Range | $946.69 - $1525.17 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.64 |
| Forward P/E | 30.0 |
| Current P/E | 32.5 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -3.5% to -5.6% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.6pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-12.47), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.58% (CS: 7) | Weak |
| RSI_14 | 39.3 | Neutral |
| MACD Histogram | -12.47 | Bearish |
| vs SMA20 | 0.958x | Below |
| vs SMA50 | 0.986x | Below |
| vs SMA200 | 1.103x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1371.42
- **Stop Loss:** $1298.12 (5.3% risk)
- **Target:** $1444.72 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 4
- **Position Value:** $5,485.68
- **Portfolio %:** 5.49%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $12.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $10.66 | $11.15 | +4.6% |
| 2025Q2 | $9.60 | $10.09 | +5.1% |
| 2025Q1 | $7.88 | $8.19 | +3.9% |
| 2024Q4 | $11.72 | $12.41 | +5.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*